Targeted Alpha Therapy Market Size To Hit USD 11.52 Billion By 2035 From USD 1.25 Billion In 2025 At CAGR Of 24.9% - SNS Insider
Austin, United States, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Targeted Alpha Therapy Market Size & Growth Analysis:
According to SNS Insider, The Targeted Alpha Therapy Market size was valued at USD 1.25 Billion in 2025 and is expected to reach USD 11.52 Billion by 2035, growing at a CAGR of 24.9% from 2026 to 2035. Demand is rising as high-energy, short-range alpha particle radiation is delivered to tumor sites without damaging adjacent tissue, supported by a growing number of late-stage clinical studies involving actinium-225 and lead-212 labeled radioligands, rising adoption of PSMA-targeted alpha therapies for prostate cancer, and increased regulatory approvals of alpha-emitter radiopharmaceuticals.
Strategic licensing deals, supply agreements, and manufacturing initiatives are playing an important role in targeted alpha therapy market modernization, as pharmaceutical companies, biotechnology firms, and radioisotope manufacturers invest heavily to build efficient alpha-emitter supply chains.
Download the Targeted Alpha Therapy Market Sample Report:
Targeted Alpha Therapy Market Key Highlights
- Market size, 2025: USD 1.25 Billion Market size, 2026E: USD 1.56 Billion Market forecast, 2035: USD 11.52 Billion CAGR: 24.9% from 2026 to 2035 Largest region: North America, approximately 42.60% share in 2025 Fastest-growing region: Asia Pacific, approximately 28.30% CAGR Largest isotope type: Radium-223, approximately 39% share in 2025 Fastest-growing isotope type: Actinium-225 Largest therapy type: Radioligand Therapy, approximately 61% share in 2025 Fastest-growing therapy type: Radioimmunotherapy Largest indication: Prostate Cancer, approximately 47% share in 2025 Fastest-growing indication: Leukemia & Hematologic Malignancies Largest end user: Hospitals & Cancer Treatment Centers, approximately 54% share in 2025 Fastest-growing end user: Specialty Oncology Clinics & Radiopharmacies
Market Relevance
Targeted alpha therapy has become an increasingly important precision oncology approach, delivering high-energy, short-range alpha particle radiation directly to tumor sites while sparing adjacent healthy tissue. Rising late-stage clinical pipeline momentum for actinium-225, lead-212, and radium-223-based radioligands, along with growing physician awareness of PSMA-targeted and somatostatin receptor-targeted approaches, continues to expand demand for therapies offering enhanced safety differentiation over beta-emitter and systemic treatments.
Targeted Alpha Therapy Market Overview
The market comprises radium-223, actinium-225, and lead-212 labeled radioligand and radioimmunotherapy products delivered across hospitals, cancer treatment centers, and specialty oncology clinics. Radium-223 remains the sole alpha particle radiopharmaceutical with a proven commercialization and reimbursement path, using a bone-targeting calcium-mimetic mechanism, while actinium-225 labeled PSMA- and CD33-targeted radioligands are advancing through late-phase development for prostate cancer and hematologic malignancies. Radioligand therapy, consisting of small molecules and peptides conjugated with alpha-emitters, remains central to prostate and neuroendocrine tumor treatment, while radioimmunotherapy using alpha-emitting antibody constructs is expanding into leukemia and multiple myeloma indications.
Strategic Market Outlook
Opportunities for growth lie in expanding indication pipelines beyond prostate cancer and neuroendocrine tumors into solid tumors, glioblastoma, and additional hematologic malignancies, with early movers positioned to capture share in a growing addressable patient pool. Development of decentralized radiopharmacy infrastructure presents a further opportunity, as manufacturers investing early in production capacity are positioned to capture share as alpha-emitter therapies scale from niche clinical use into a larger oncology product category.
Isotope supply constraints and complex manufacturing and regulatory requirements remain major restraints. Global shortages of key alpha emitters such as actinium-225 stem from dependency on a limited number of national laboratories and commercial producers lacking scale-up capability, while special radiation handling requirements, chelating chemistry, and short half-lives make manufacturing and licensing processes costly and difficult for biotech companies entering the field.
Targeted Alpha Therapy Market Regional Analysis
North America held approximately 42.60% of the global market in 2025, making it the largest region, supported by strong late-stage clinical trial activity, nuclear medicine infrastructure, and a strong presence of radioligand manufacturers including Novartis, Convergent Therapeutics, Fusion Pharmaceuticals, and Actinium Pharmaceuticals. The United States accounted for approximately 85.90% of North American revenue, supported by Department of Energy-backed isotope manufacturing initiatives and Bayer's Xofigo, while Canada contributes through Canadian Nuclear Laboratories' radioisotope manufacturing capability.
The U.S. Targeted Alpha Therapy Market was valued at approximately USD 0.46 Billion in 2025 and is expected to reach approximately USD 4.05 Billion by 2035, growing at a CAGR of approximately 24.4% from 2026 to 2035.
The Europe Targeted Alpha Therapy Market held approximately 31% of the global market in 2025, valued at USD 0.39 Billion, and is expected to reach USD 3.37 Billion by 2035, growing at a CAGR of 23.80% from 2026 to 2035. Growth is supported by favorable European Medicines Agency regulatory pathways and the EU SECURE project supporting sustainable alpha-emitter production. Germany generated approximately 25.40% of European revenue in 2025, driven by ITM Isotope Technologies Munich's isotope production, while France contributes through Orano Med and Sanofi's lead-212 based AlphaMedix development.
The Asia-Pacific region is the fastest-growing, with a projected CAGR of approximately 28.30% from 2026 to 2035, driven by rising cancer research expenditure and expanding radiopharmaceuticals manufacturing investment. Japan led the region, supported by joint efforts between national research institutes and cancer centers to develop alpha emitter radioligands domestically, while China and South Korea contribute through growing clinical trial networks.
Buy the Targeted Alpha Therapy Market Report with Competitive Analysis and 2035 Forecast:
Targeted Alpha Therapy Market Segment Analysis
By Isotope Type: Radium-223 accounted for around 39% market share in 2025, supported by its proven clinical history and Bayer's FDA-approved Xofigo for bone-metastatic castration-resistant prostate cancer. Actinium-225 is the fastest-growing segment, driven by a growing number of late-phase PSMA-targeted and CD33-targeted radioligands under pivotal study.
By Therapy Type: Radioligand Therapy accounted for around 61% market share in 2025, driven by clinical advancement of PSMA-targeted and somatostatin receptor-targeted small molecules and peptides. Radioimmunotherapy is the fastest-growing therapy type, driven by development of alpha-emitting antibody constructs targeting CD33, CD38, and CD45 for hematological cancers.
By Indication: Prostate Cancer accounted for around 47% market share in 2025, supported by radium-223's proven use and a robust pipeline of PSMA-targeted actinium-225 and lead-212 radioligands. Leukemia & Hematologic Malignancies is the fastest-growing indication, driven by increasing clinical development of CD33- and CD38-targeted actinium-225 immunoconjugates.
By End User: Hospitals & Cancer Treatment Centers accounted for around 54% market share in 2025, supported by radiation safety infrastructure and nuclear medicine department capability. Specialty Oncology Clinics & Radiopharmacies is the fastest-growing segment, driven by expanding radiopharmacy networks that extend treatment access to communities outside major academic hospital systems.
Targeted Alpha Therapy Market Key Trends
- Expanding late-stage clinical pipeline of actinium-225 and lead-212 labeled radioligands accelerating commercial-scale adoption Growing PSMA-targeted radioligand development strengthening prostate cancer as the leading indication Rising strategic licensing and co-development agreements expanding global alpha therapy pipelines Increasing FDA and EMA regulatory support accelerating breakthrough therapy designations Growing investment in dedicated isotope supply chains easing production bottlenecks
Major key players include
- Novartis AG Bayer AG Telix Pharmaceuticals Limited Fusion Pharmaceuticals Inc. (AstraZeneca) Eli Lilly and Company Bristol Myers Squibb Company Orano Med Sanofi Convergent Therapeutics, Inc. AdvanCell Actinium Pharmaceuticals, Inc. Perspective Therapeutics, Inc. Ratio Therapeutics Aktis Oncology NorthStar Medical Radioisotopes, LLC Eckert & Ziegler Radiopharma GmbH ITM Isotope Technologies Munich SE Ion Beam Applications SA (IBA) Cardinal Health, Inc. Curium Pharma
Explore the Complete Targeted Alpha Therapy Market Report:
CONTACT: About Us: SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world. Contact Us: Rohan Jadhav - Principal Consultant Phone: +1-315-961-9094 (US) Email:...
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment